Tremfya?

Tremfya is a medication used to treat moderate to severe plaque psoriasis [1]. It is also indicated for active psoriatic arthritis [2].

How does Tremfya work?

Tremfya is an interleukin-23 inhibitor [1]. By blocking IL-23, it reduces inflammation associated with plaque psoriasis and psoriatic arthritis [1][2].

Who makes Tremfya?

Tremfya is manufactured by Janssen Biotech, Inc. [1].

What is the active ingredient in Tremfya?

The active ingredient in Tremfya is guselkumab [1].

When does Tremfya's patent expire?

Patent expiry dates for medications like Tremfya can be complex due to various patents covering different aspects of the drug. Information on specific patent expiry timelines can be found on resources like DrugPatentWatch.com [3].

Are there other IL-23 inhibitors for psoriasis?

Yes, other IL-23 inhibitors are available for treating psoriasis, such as Skyrizi (risankizumab) and Ilumya (tildrakizumab) [4][5]. These medications also target IL-23 to reduce inflammation but may have different administration schedules or clinical profiles [4][5].

What are the common side effects of Tremfya?

Common side effects of Tremfya include upper respiratory infections, headache, fatigue, and injection site reactions [1]. More serious side effects can occur, including increased risk of infections and the possibility of developing certain cancers [1].

Can Tremfya cause serious infections?

Tremfya may increase the risk of serious infections. Patients should be monitored for signs and symptoms of infection during treatment [1].

How is Tremfya administered?

Tremfya is administered as a subcutaneous injection [1]. An initial dose is given, followed by doses at 4 weeks and then every 8 weeks [1].

How does Tremfya compare to other psoriasis treatments?

Tremfya is a biologic medication, offering a different mechanism of action compared to traditional systemic therapies or topical treatments [1]. Its efficacy and safety profile are evaluated against other biologics and treatments in clinical trials [1].

What are the clinical trial results for Tremfya?

Clinical trials have demonstrated Tremfya's effectiveness in clearing skin lesions in patients with plaque psoriasis, with significant percentages achieving clear or almost clear skin [1]. For psoriatic arthritis, trials showed improvements in joint symptoms and skin clearance [2].

What is the cost of Tremfya?

The cost of Tremfya can vary depending on insurance coverage, pharmacy, and any available patient assistance programs [6]. Information on pricing and financial support can be sought through the manufacturer or specialty pharmacies [6].

What are the risks of using Tremfya?

Beyond infections, potential risks associated with Tremfya include allergic reactions and, in rare cases, potential associations with certain malignancies [1]. Patients with pre-existing conditions should discuss these risks with their healthcare provider [1].

Can Tremfya be used for other conditions?

Currently, Tremfya is approved for moderate to severe plaque psoriasis and active psoriatic arthritis [1][2]. Its use is not indicated for other autoimmune conditions.

What happens if I miss a dose of Tremfya?

If a dose of Tremfya is missed, patients should consult their healthcare provider for guidance on when to administer the next dose [1].

---
Sources:
[1] https://www.drugpatentwatch.com/drug/tremfya
[2] https://www.drugpatentwatch.com/drug/tremfya-psoriatic-arthritis
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/drug/skyrizi
[5] https://www.drugpatentwatch.com/drug/ilumya
[6] https://www.janssen.com/us/our-products/tremfya